Sanuwave Health (SNWV)
NASDAQ:SNWV
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$16.72 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$159.94M
Enterprise Value$170.95M
Total Cash (Recent Filing)$11.96M
Total Debt (Recent Filing)$22.97M
Price to Earnings (P/E)21.6
Beta0.91
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding8,594,209
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue3.88
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda27.45
Forecast
1Y Price Target
$51.00Price Target Upside62.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.94
Revenue Forecast (FY)$57.95M
Bulls Say, Bears Say
Bulls Say
2025 Revenue & Profit TurnaroundA clear 2025 turnaround with meaningful revenue growth and positive net income indicates the business can scale to profitability. Durable improvement suggests product-market fit and reduced dependence on capital raises, improving the company's long-term self-funding and strategic optionality if sustained.
High Gross MarginsSustained ~77% gross margins point to strong unit economics and pricing power in the core shockwave therapy. High margins provide buffer for sales/marketing investment, support long-term profitability as volumes grow, and make the business more resilient to cost shocks if maintained.
Expanding Commercial FootprintRecord system placements and new distributor interest expand the installed base and channels. A larger installed base drives recurring consumables and service revenue, creates distributor incentives, and builds durable competitive advantage via network reach and customer relationships.
Bears Say
Thin Equity / Elevated LeverageDespite lower debt, very thin equity and high debt-to-equity leave little cushion for operational shocks. This structural fragility increases refinancing and covenant risk, limits strategic flexibility, and raises the likelihood of dilutive financing if growth weakens or unexpected expenses arise.
Weak Cash ConversionOperating cash flow that is a small fraction of reported earnings signals earnings may not fully convert to cash. Persistent weak cash conversion constrains reinvestment, heightens liquidity risk, and can force reliance on external capital despite reported profitability, undermining long-term financial health.
Reimbursement & Market Disruption RiskDependence on reimbursement policies exposes demand to regulatory shifts and payer audits. Policy-driven capital-budget freezes and provider exits can materially compress addressable demand and revenue visibility, making growth and profitability outcomes contingent on factors outside company control.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $16.72 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $159.94M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is May 08, 2026 which is in 39 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on Mar 27, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.7.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,594,209 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of $0.87 in its last earnings report, beating expectations of $0.17. Following the earnings report the stock price went down -1.273%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.00 (62.94% Upside)
$51.00 (62.94% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
84.41%
Trailing 12-Months
Asset Growth
62.97%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
SNWV Company Deck
SNWV Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
SANUWAVE achieved record-breaking quarterly revenue and significant system sales, indicating strong growth and market presence. However, the company faced challenges in meeting its revenue guidance due to market uncertainty and disruption. Despite these challenges, the outlook for reimbursement changes is positive, and September showed strong performance, suggesting potential future growth.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$51.00
▲(62.94% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
27.60% Insiders
7.34% Mutual Funds
24.72% Other Institutional Investors
32.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---